Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains

23 Jan 2024

Abstract excerpt

Since the start of the SARS-CoV-2 pandemic, the search for antiviral therapies has been at the forefront of medical research. To date, the 3CLpro inhibitor nirmatrelvir (Paxlovid®) has shown the best results in clinical trials and the greatest robustness against variants. A second SARS-CoV-2 protease inhibitor, ensitrelvir (Xocova®), has been developed. Ensitrelvir, currently in Phase 3, was approved in Japan...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to SARS-CoV-2 and COVID-19 Research
Share to SARS-CoV-2 detection and testing
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38272321
DOI: 10.1016/j.antiviral.2024.105814

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strainsPMID 38272321Read ↗

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strainsSemantic proximity Read ↗

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSemantic proximity Read ↗

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSemantic proximity Read ↗

Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance.Semantic proximity Read ↗

A comprehensive study of SARS-CoV-2 main protease (M <sup>pro</sup> ) inhibitor-resistant mutants selected in a VSV-based systemSemantic proximity Read ↗

A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system.Semantic proximity Read ↗

Monitoring for SARS-CoV-2 drug resistance mutations in broad viral populationsSemantic proximity Read ↗

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvirSemantic proximity Read ↗

In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvirSemantic proximity Read ↗

Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrierSemantic proximity Read ↗

Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical geneticsSemantic proximity Read ↗

Highly specific SARS-CoV-2 main protease (Mpro) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.